AU2147192A - Method of stimulating immune response using growth hormone - Google Patents

Method of stimulating immune response using growth hormone

Info

Publication number
AU2147192A
AU2147192A AU21471/92A AU2147192A AU2147192A AU 2147192 A AU2147192 A AU 2147192A AU 21471/92 A AU21471/92 A AU 21471/92A AU 2147192 A AU2147192 A AU 2147192A AU 2147192 A AU2147192 A AU 2147192A
Authority
AU
Australia
Prior art keywords
immune response
growth hormone
stimulating immune
stimulating
hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21471/92A
Inventor
Lena Mariana Susann Carlsson
Ross G Clark
Michael J Cronin
Paula M. Jardieu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2147192A publication Critical patent/AU2147192A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU21471/92A 1991-06-28 1992-05-29 Method of stimulating immune response using growth hormone Abandoned AU2147192A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72335991A 1991-06-28 1991-06-28
US723359 1991-06-28

Publications (1)

Publication Number Publication Date
AU2147192A true AU2147192A (en) 1993-01-25

Family

ID=24905890

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21471/92A Abandoned AU2147192A (en) 1991-06-28 1992-05-29 Method of stimulating immune response using growth hormone

Country Status (3)

Country Link
AU (1) AU2147192A (en)
PT (1) PT100629A (en)
WO (1) WO1993000109A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
ATE196548T1 (en) 1991-05-10 2000-10-15 Genentech Inc SELECTING AGONISTS AND ANTAGONISTS OF LIGANDS
AU1554295A (en) * 1994-01-05 1995-08-01 Biomedtech Engineering, Inc. Method for treatment and prevention of disease in animals
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5661122A (en) * 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
DE69638117D1 (en) * 1995-09-21 2010-03-04 Genentech Inc Variants of human growth hormone
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP0981618B2 (en) 1997-05-15 2011-08-24 Genentech, Inc. Anti-apo-2 antibody
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ES2297889T3 (en) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. DERIVATIVES OF HORMONE OF GROWTH AND RELATED PROTEINS.
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
ES2331901T3 (en) 1998-06-12 2010-01-19 Genentech, Inc. MONOCLONAL ANTIBODIES, ANTIBODIES THAT REACT IN A CROSSED FORM AND PROCEDURE FOR THE PRODUCTION OF THE SAME.
DK1656952T3 (en) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylene glycol conjugates of interferon beta-1A and applications thereof
MXPA01003790A (en) 1998-10-16 2002-09-18 Biogen Inc Interferon-beta fusion proteins and uses.
DE69919969T2 (en) * 1998-12-17 2005-09-29 Applied Research Systems Ars Holding N.V. Human growth hormone for stimulating hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU7485301A (en) 2000-05-16 2001-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
DK1299727T3 (en) 2000-07-12 2009-06-15 Agensys Inc Hitherto unknown tumor antigen suitable for diagnosis and treatment of bladder, ovarian, lung, and renal cancer types
US20040186051A1 (en) 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
DK1578771T3 (en) * 2001-10-10 2013-06-10 Novo Nordisk As Remodeling and glycoconjugation of peptides
AP2004003050A0 (en) * 2001-11-20 2004-06-30 Pharmacia Corp Chemically modified human growth hormone conjugates
PT1463751E (en) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albumin fusion proteins
EP1556076A4 (en) 2002-06-24 2009-07-08 Genentech Inc Apo-2 ligand/trail variants and uses thereof
JP5207590B2 (en) 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Polymer conjugate of interferon-beta with enhanced biological ability
MXPA06008126A (en) 2004-01-14 2008-02-14 Univ Ohio Methods of producing peptides/proteins in plants and peptides/proteins produced thereby.
WO2005110015A2 (en) 2004-04-19 2005-11-24 Ohio University Cross-linkable glycoproteins and methods of making the same
EP1789092A2 (en) * 2004-08-31 2007-05-30 Pharmacia & Upjohn Company LLC Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
JP2008516621A (en) * 2004-10-18 2008-05-22 ノボ ノルディスク アクティーゼルスカブ Growth hormone conjugate
EP1850878A2 (en) 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
US8329866B2 (en) 2005-10-03 2012-12-11 Bolder Biotechnology, Inc. Long acting VEGF inhibitors and methods of use
BRPI0713963A2 (en) 2006-07-07 2012-11-27 Novo Nordisk Healthcare Ag protein conjugates and methods for their preparation
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
US20100105620A1 (en) 2008-10-10 2010-04-29 Anaphore, Inc. Polypeptides that bind Trail-R1 and Trail-R2
MX2013012716A (en) 2011-05-03 2014-03-21 Genentech Inc Vascular disruption agents and uses thereof.
MX366115B (en) 2013-03-14 2019-06-27 Univ Massachusetts Methods of inhibiting cataracts and presbyopia.
CN107318267B (en) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 Compositions and methods for treating complement-associated disorders
WO2015106003A1 (en) 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Ras pathways as markers of protection against hiv and methods to improve vaccine efficacy
BR112016025312A2 (en) 2014-05-01 2017-10-17 Genentech Inc antibody variants, anti-d-factor antibody, pharmaceutical formulation, dispensing device, use of the formulation and a composition, composition and method of treating a disorder
JP7305300B2 (en) 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Combination immunotherapy
CN108289951A (en) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 Anti- factor D antibody and conjugate
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
EA035402B1 (en) 2015-11-13 2020-06-08 Зе Юниверсити Оф Массачусеттс Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia
TW202014207A (en) 2018-04-30 2020-04-16 英商梅迪繆思有限公司 Conjugates for targeting and clearing aggregates
US11999787B2 (en) 2020-03-24 2024-06-04 Genentech, Inc. Tie2-binding agents and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US4837202A (en) * 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
ATE136315T1 (en) * 1989-05-27 1996-04-15 Sumitomo Pharma METHOD FOR THE PRODUCTION OF POLYETHYLENE GLYCOL DERIVATIVES AND MODIFIED PROTEINS.
EP0458064B1 (en) * 1990-05-04 1998-02-25 American Cyanamid Company Stabilization of somatotropins by modification of cysteine residues
GB9010058D0 (en) * 1990-05-04 1990-06-27 Health Lab Service Board Method and composition for the treatment of cancer

Also Published As

Publication number Publication date
PT100629A (en) 1993-09-30
WO1993000109A1 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
AU2147192A (en) Method of stimulating immune response using growth hormone
AU682414B2 (en) Stimulation of growth hormone responsive tissues
GB9215744D0 (en) Method of raising fish
AU2455092A (en) Method of preparing sunscreens
PL327634A1 (en) Growth hormone secretion stimulating compounds
CS135591A2 (en) Method of peptide preparation
AU1298392A (en) Stimulating factor of the neu receptor
PL294868A1 (en) Method of obtaining vinyl acetate
AU4242193A (en) Method of preparing reduced fat spreads
AU3011692A (en) Horseshoes and method for their preparation
EP0510382A3 (en) Method of preparation of alpha-omega-aminoalcohols
AU1306092A (en) Method of preparing oxide superconducting wire
AU4647993A (en) Method of stimulating the immune system
AU7082487A (en) Recombinant human b-cell growth factor
AU1303492A (en) Method of preparing oxide superconducting wire
AU1779192A (en) Method of treatment using steroid mouthwash
AU5149793A (en) Method of preparing aminoalkylhydantoins and aminoalkyl-alpha-aminoacids
AU1297492A (en) Method of preparing polyethercyclicpolyols
AU1297592A (en) Method of preparing polyethercyclicopolyols
RU2003311C1 (en) Method of blepharorrhaphy
AU2512492A (en) Method of preparing reduced fat foods
AU1252492A (en) Stimulation of hair growth by phospholipids
AU2447792A (en) Element and method of preparing this element
AU5881996A (en) Methods of treatment using growth hormone antagonists
AU647999C (en) Pain controlling composition and method of preparation